Le Lézard
Classified in: Health
Subject: NEW PRODUCTS/SERVICES

Doheny Eye Institute Announces New Headquarters in Pasadena


LOS ANGELES, CA--(Marketwired - November 22, 2017) - Doheny Eye Institute, a top-ranked nonprofit organization proudly affiliated with UCLA Stein Eye Institute and dedicated to furthering the conservation, improvement and restoration of human eyesight since 1947, is pleased to announce the purchase of its new headquarters in Pasadena. The new 123,200-square foot 7-acre commercial property at 150 North Orange Grove Boulevard will be the new home for Doheny Eye Institute, one of the world's most prestigious clinical vision research organizations.

Designed by the iconic architect group William L. Pereira & Associates, creators of the original Los Angeles County Museum of Art (LACMA) campus and the Transamerica Pyramid in San Francisco, this LEED Silver -contemporary property, originally built in 1981 was the former headquarters of the Avery Dennison Corporation. The building, within walking distance to Old Pasadena, award-winning restaurants and shopping in the heart of downtown Pasadena, the Norton Simon Museum, the Pasadena Museum of History, and the Tournament of Roses will serve as the new home to Doheny's vision research center, operating suites and clinical space.

"We are thrilled about our move into the new Pasadena campus," said SriniVas R. Sadda, MD President & Chief Scientific Officer, Doheny Eye Institute. "The longstanding legacy of Doheny and historic Pasadena are a perfect match. We look forward to calling Pasadena home as we continue to further Doheny Eye Institute's vision -- to have the greatest impact on human eyesight by leading our field with groundbreaking research, superior education programs, and the best eye care in the world."

The Pasadena property sold for just under $50 million. Doheny will develop plans for the design of the interior renovations as soon as possible. "The new campus is contemporary, welcoming and fresh, and we are excited to provide this experience to the faculty, staff, patients and visitors," adds Marissa Goldberg, Doheny's Executive Director and Chief Financial Officer. "City of Pasadena representatives have been very supportive and helpful at every step of the way in our search for our new property."

For a sneak peek of the new Pasadena location, click here.

About Doheny Eye Institute
For 70 years, Doheny Eye Institute has been at the forefront of vision science. From seeking new ways to free blockages that prevent fluid drainage in glaucoma, to replacing retinal cells in age-related macular degeneration, to providing colleagues worldwide with standardized analyses of anatomical changes in the eyes of patients, Doheny clinicians and scientists are changing how people see -- and also how they think about the future of vision.

Doheny Eye Institute and UCLA Stein Eye Institute have joined forces to offer the best in patient care, vision research and education. This affiliation combines the strength, reputation and distinction of two of the nation's top eye institutions to advance vision research, education and patient care in Southern California.


These press releases may also interest you

at 04:00
Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the launch of SUBMIT24 in its beta version during Q3 2024,...

at 04:00
TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and...

at 03:26
Calliditas Therapeutics AB , ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine...

at 03:00
Flindr...

at 03:00
CSL Vifor and Travere Therapeutics, Inc., today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the...

at 03:00
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates. The...



News published on and distributed by: